NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









SolasCure

SolasCure

Private
CambridgeHealthcare & Life Scienceshttps://www.solascure.com/

Last Round

Accelerator

Jun 3, 2024

Total Funding Raised

$34.44M

Company Overview

SolasCure is a biotechnology company developing Aurase Wound Gel, a hydrogel-based therapeutic that uses a recombinant enzyme to debride chronic wounds and activate tissue repair.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

wound carebiologic therapyenzymatic debridementchronic wound healingbiotechmaggot therapyhydrogelvenous leg ulcersclinical stage biotechnecrotic tissue removalbiopharmaceuticalwound managementcalciphylaxis treatmenttopical biologicregenerative medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SolasCure Comparables

Compare SolasCure with similar companies based on industry and business-model similarity.

SolasCure comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ilya Pharma
81%
Mediwound Ltd
78%
Biotherapy Services
76%

SolasCure Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorJun 3, 2024
GrantMar 20, 2024
GrantJun 1, 2023
Series BMar 27, 2023
GrantJan 11, 2023
Series A
Oct 8, 2021

Key People

Founding team and executive leadership

Lee Harle

Chief Executive Officer

Executive Team

Bela Kelety

Chief Technology Officer

Executive Team

Oliver Schofield

Chief Financial Officer

Executive Team

SolasCure Investors

Notable investors and investment history

SolasCure investors
InvestorRounds
Innovate UKGrant
European Innovation Council FundGrant
Seneca PartnersSeries A, Series B
Innovate UKAccelerator, Grant
Texas Medical CenterAccelerator
Bionova CapitalSeries A
Wealth ClubSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2023

    Received grant funding from the European Innovation Council.

  • Mar 27, 2023

    $13.3M round led by Seneca Partners.

SolasCure Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

SolasCure Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about SolasCure's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range17
Year Founded2017
Last FundingJun 3, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.